期刊
JOURNAL OF CLINICAL ONCOLOGY
卷 21, 期 8, 页码 1637-1647出版社
AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2003.11.143
关键词
-
类别
The introduction of imatinib, a specific inhibitor of the Bcr-Abl tyrosine kinase, has dramatically changed the management of chronic myeloid leukemia (CML). More than 10,000 patients worldwide have been treated with imatinib in clinical trials, and a large body of information has accumulated about the use of this drug. The purpose of this article is to review practical guidelines in regard to optimal dosing, monitoring, managing common side effects such as myelosuppression, and potential drug interactions. The treatment recommendations are intended to optimize therapy with imatinib while taking into account a patient's specific circumstances. J Clin Oncol 21:1637-1647. (C) 2003 by American Society of Clinical Oncology.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据